skip to main content
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Products

Show More

Show More

9 Total results for product and free and sample content found

Scrip

Health Sector On High Alert As Wuhan Coronavirus Spreads

By Brian Yang 27 Nov 2020

Health_Sector_On_High_Alert

The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”

Topic China Infectious Diseases Policy & Regulation Coronavirus

Medtech Insight

Diagnostics Sector On High Alert As Wuhan Coronavirus Spreads

By Brian Yang 27 Nov 2020

Diagnostics_Sector_On_High_Alert

The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, diagnostics companies are rushing to have test kits ready.

Topic China In Vitro Diagnostics Coronavirus

Pink Sheet

China Regulatory Express Former CFDA Commissioner Bi Makes Comeback

By Brian Yang 27 Nov 2020

CFDA China Forbidden City

Ex-China FDA Commissioner Bi Jingquan’s new role, a waiver of bioequivalence testing for hundreds of drugs, data accuracy requirements and a new crackdown on compliance issues.

Topic China Regulation Compliance

Pink Sheet

China Coronavirus Outbreak Response Critical As First US Case Confirmed

By Brian Yang 27 Nov 2020

China_Coronavirus_Outbreak_Response_Critical

A quickly spreading coronavirus outbreak in China could upend the country’s healthcare priorities as the health regulators and reimbursement agency officials gear up to “control and prevent” the worst public health emergency since the deadly SARS outbreak in 2003.

Topic China Coronavirus Infectious Diseases Policy & Regulation

Scrip

China Coronavirus Cases Up Sharply As Pharma Rushes To Aid

By Brian Yang 27 Nov 2020

China_Coronavirus_Cases_Up_Sharply

AbbVie’s HIV therapy Kaletra is now being used by the Chinese government to treat coronavirus-infected patients after a respiratory expert endorsed its use, while other pharma companies from Bayer to Innovent are showering support as China battles its worst virus outbreak since the SARS epidemic 17 years ago.

Topic China Coronavirus Policy & Regulation Risk Management

Scrip

Biopharma’s Coronavirus ‘Self-Isolating’: Companies Cancel Investor Meetings, Cut Back Travel

By Kevin Grogan 27 Nov 2020

Corona_Invivo

As the coronavirus spreads beyond China, biopharma companies are taking precautions, with some more wary than others.

Topic China Coronavirus

Pink Sheet

China-US Relationship Hinges On Changing Internal, External Forces

By Brian Yang 18 Nov 2020

US Election China Relations

Given the ongoing election challenges in the US, China has yet to officially congratulate Joe Biden as the next US president, although many world leaders are already hailing a reset in US foreign policy. Many are wondering if this and other moves indicate a quiet internal shift for China's high tech and life sciences sectors, just days after Beijing concluded a high-level plenary meeting outlining its priorities for the next five years.

Topic US Election 2020 China

Generics Bulletin

Celltrion Sets Out Strategy For China

By David Wallace 27 Jan 2020

Celltrion_Sets_Out_Strategy_For_China

Celltrion has unveiled plans to construct a biologics plant in Wuhan, China, as well as setting up a direct sales network in the country, as part of its wider global strategy that also involves launching a new biosimilar every year to 2030.

Topic China Manufacturing Strategy

Scrip

Scrip Asia 100 Report Extract

18 Dec 2019

Scrip_Asia_100_Content_Tile

Access Asia Pharma Intelligence expertise and hear from Pharma journalists across Asia to reveal deep regional expertise with this sample of Scrip's Asia 100 Report.

Topic Business Strategies China Company Analysis Drug Development Landscape Market Intelligence

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: